MTAP-DELETED SOLID TUMORS
Clinical trials for MTAP-DELETED SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new MTAP-DELETED SOLID TUMORS trials appear
Sign up with your email to follow new studies for MTAP-DELETED SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, BAY 3713372, in people with solid tumors that lack a gene called MTAP. The drug blocks a protein that these cancer cells need to survive, potentially killing them while leaving healthy cells alone. The trial first finds the safest dose, then tests how…
Matched conditions: MTAP-DELETED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
New hope for Hard-to-Treat cancers: targeted drug combo enters human trials
Disease control Recruiting nowThis study tests a new oral drug, S095035, alone or with another drug (TNG462), in adults with advanced solid tumors that have a specific genetic deletion (MTAP). The goal is to see if the drug is safe and shrinks tumors. About 342 participants who have tried at least one prior t…
Matched conditions: MTAP-DELETED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for Hard-to-Treat cancers: first human trial of PEP08 begins
Disease control Recruiting nowThis early-phase study tests a new drug called PEP08 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check safety, find the right dose, and see if the drug shows signs of shrinking tumors. About 40 adults who have tr…
Matched conditions: MTAP-DELETED SOLID TUMORS
Phase: PHASE1 • Sponsor: PharmaEngine • Aim: Disease control
Last updated May 08, 2026 12:02 UTC